2008
Colombian Submission to the WHO IGWG negotiation, 2008-03-07
2015
Switzerland pressures Colombia to deny compulsory license on imatinib, 2015-08-17
2016
Colombia takes an important step in defining the public interest in compulsory licensing case, 2016-03-04
Colombia Technical Committee Recommends Declaration that a Compulsory License on Imatinib (Gleevec) Would Be in Public Interest, 2016-03-04
April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license, 2016-05-11
Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster, 2016-05-11
News reports on Senator Hatch pressure over Colombia compulsory license on Novartis drug, 2016-05-16
122 experts defend Colombia’s right to issue compulsory license on imatinib in face of U.S. pressure, 2016-05-18
Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License, 2016-05-19
Background FAQ on Glivec (imatinib) compulsory license in Colombia, 2016-05-19
Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib, 2016-05-25
WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies, 2016-05-25
15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia, 2016-05-26
Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug, 2016-05-27
WHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license, 2016-05-28
28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug, 2016-05-28
Colombia Ministry of Health Announces that Negotiations With Novartis Have Failed; Declaration of Public Interest Imminent, 2016-06-09
US Chamber of Commerce defends Swiss drug company charging excessive prices in Colombia, 2016-06-10
Colombia Issues Public Interest Declaration To Lower Price of Glivec, 2016-06-15
Colombia finalizes 44% price reduction of leukemia drug Glivec, 2016-12-21
2017
FOIA documents. In 2015 Novartis asked U.S. Dept of Commerce to Pressure Colombia Against Compulsory License on Glivec, 2017-06-08
SCP27: KEI statement on pressures faced by Brazil and Colombia in using TRIPS flexibilities, 2017-12-13
2018
PhRMA letter on Colombia Resolution 5246, 2018-01-16